Possible link between antidepressant use in pregnancy and autism

Monday, 06 May, 2019

Possible link between antidepressant use in pregnancy and autism

An international team led by Duke-NUS Medical School, a school of the National University of Singapore, has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in the womb.

Antidepressants are commonly prescribed for treating major depression and post-traumatic stress disorder, including in pregnant women. One of the most commonly prescribed antidepressants is fluoxetine, a serotonin reuptake inhibitor. Fluoxetine can cross the placenta and is also detected in breast milk. Little is known about its safety during pregnancy.

As noted by Associate Professor Hyunsoo Shawn Je, from Duke-NUS’s Neuroscience and Behavioural Disorders (NBD) Programme, many human association studies have been conducted to investigate connections between antidepressant exposure during pregnancy and children with autism and attention deficit disorder, but a causal relationship has not yet been pinpointed. With this in mind, the team from Duke-NUS and their collaborators investigated adult mice born to mothers treated with fluoxetine (sold under the brand names Prozac and Sarafem) over a 15-day time period that corresponds to the second trimester in humans, in comparison with those born to mothers given normal saline as controls.

Writing in the journal Molecular Brain, the researchers claim to have found key differences in behaviour. For example, the unexposed mice explored all three arms of a Y-shaped maze over a 10-minute time period, typically preferring to explore a previously uncharted arm of the maze rather than return to a previously visited arm. The fluoxetine-exposed mice were less inclined to explore an unvisited arm.

In a second experiment, the mice were introduced to two juvenile mice, one after the other. When the second new mouse was introduced, mice that were not exposed to fluoxetine were more likely to only sniff the newly introduced mouse, recognising that they had already met the first mouse. But the fluoxetine-exposed group sniffed both mice, indicating that they had impaired social novelty recognition.

The team then examined nerve signal transmission in the prefrontal cortex, a part of the brain involved in moderating social behaviour. They found impaired transmission caused by an overactive serotonin receptor. Treating fluoxetine-exposed mice with a compound that blocks the receptor alleviated their behavioural problems and improved their working memory.

The team next want to examine autistic children born to mothers treated with antidepressants using positron emission tomography (PET) scans, an imaging technique used to observe metabolic processes in the body. If they also show enhanced serotonin receptor activity in the same area of the brain, the team plans to test whether FDA-approved serotonin receptor blockers can normalise their behaviours.

“The consensus among experts is that the rise in the number of people diagnosed with autism around the world is likely due to more awareness and testing rather than an increase in the prevalence of autism,” noted Professor Patrick Casey, Senior Vice Dean for Research at Duke-NUS. “This collaborative study by our researchers offers a compelling case for a link between autism and antidepressant exposure in the womb in an animal model, and a possible mechanism that could potentially be exploited for future therapies.”

Image credit: ©stock.adobe.com/au/BillionPhotos.com

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

Major Project Status granted for medical cannabis facilities

The Australian Government is looking to maximise the economic potential of the medicinal cannabis...

Brain biomarker can predict compulsive drinking

Researchers have discovered a brain circuit that controls alcohol drinking behaviour in mice, and...

Blocking a survival mechanism in melanoma

The effectiveness of current treatments for melanoma could be improved by using approaches that...

  • All content Copyright © 2019 Westwick-Farrow Pty Ltd